公开(公告)号：US20070192906A1

公开(公告)日：2007-08-16

申请号：US11547910

申请日：2005-04-08

申请人： Yoshikazu Yuki ,  Hiroshi Kiyono ,  Takachika Hiroi ,  Tomonori Nochi ,  Fumio Takaiwa ,  Hidenori Takagi ,  Lijyun Yang ,  Kazuya Suzuki ,  Hiroyasu Ebinuma ,  Koichi Sugita ,  Saori Kasahara

发明人： Yoshikazu Yuki ,  Hiroshi Kiyono ,  Takachika Hiroi ,  Tomonori Nochi ,  Fumio Takaiwa ,  Hidenori Takagi ,  Lijyun Yang ,  Kazuya Suzuki ,  Hiroyasu Ebinuma ,  Koichi Sugita ,  Saori Kasahara

IPC分类号： A01H5/00 ,  A61K39/00 ,  C12N15/82

CPC分类号： A61K39/08 ,  A23L7/196 ,  A23V2002/00 ,  A61K39/107 ,  A61K39/12 ,  A61K39/21 ,  C07K14/005 ,  C07K2319/55 ,  C12N15/8258 ,  C12N2740/16122 ,  C12N2740/16134 ,  A23V2300/21

摘要： To provide a transgenic rice plant that can produce rice which can be used as an “edible vaccine”, i.e., rice capable of inducing a desired immune response when mucosally administered such as an oral administration. There is provided a transgenic rice plant including a genomic DNA, wherein a DNA construct is incorporated into the genomic DNA so that the DNA construct is capable of being expressed, wherein the DNA construct includes a DNA encoding an antigenic protein, and a rice endosperm specific promoter linked upstream thereof.

摘要翻译： 提供可以产生可以用作“可食用疫苗”的水稻的转基因水稻植物，即当粘膜给药如口服给药时能够诱导所需免疫应答的水稻。 提供了包括基因组DNA的转基因水稻植物，其中将DNA构建体并入基因组DNA中，使得DNA构建体能够被表达，其中所述DNA构建体包括编码抗原蛋白的DNA和水稻胚乳特异性 启动子连接上游。

公开(公告)号：US20120245050A1

公开(公告)日：2012-09-27

申请号：US13498267

申请日：2010-10-25

申请人： Takachika Hiroi ,  Kimihiro Okubo

发明人： Takachika Hiroi ,  Kimihiro Okubo

IPC分类号： C40B30/04

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： [Problem] To provide a biomarker for predicting the therapeutic efficacy of allergen immunotherapy.[Means for solving the problem] A method for detecting the efficacy of allergen immunotherapy, the method comprising the steps of: detecting a copy number variation of at least one gene selected from the gene group, AGXT2L2, AZGP1, CAV3, CEP72, CUL4A, CXCR7, C12orf60, C16orf48, C19orf34, DNAJB8, FTH1, GEMIN4, GIGYF2, GJC3, HTT, ITCH, MARK2, METT10D, NAV3, NOB1, PAFAH2, PLEKHG4B, PPFIA1, SCARNA11, SDF2L1, SMPD3, SNORA44, SRP14, ST6GALNAC1, SULF2, TMED6, TYRP1, WFDC13, ZNFX1, NCAM2, PCDH17, CHODL, BTG3, DIAPH3, GBA3, IFRD1, KCNT2, THOC7, TMEM168, BST1, C7orf53, CD38, DCUN1D1, FGFBP1, FOXP2, GLRB, GTF2B, HSP90AB2P, MCCC1, MDFIC, ODF2L, PDGFC, SEP15, SH3GLB1, TDRD3, YEATS2, CCDC127, C14orf180, SIVA1, TNFRSF14, AHNAK2, C14orf79, LOC25845, PLD4, GPR132, LOC389257, BRF1 and ADSSL1, from a specimen to be examined collected from the subject; and correlating the obtained result from detecting the copy number variation with effectiveness of the allergen immunotherapy.

摘要翻译： [问题]提供用于预测变应原免疫治疗的治疗功效的生物标志物。 [解决问题的手段]一种检测变应原免疫治疗效果的方法，所述方法包括以下步骤：检测选自基因组AGXT2L2，AZGP1，CAV3，CEP72，CUL4A中的至少一种基因的拷贝数变异， CXCR7，C12orf60，C16orf48，C19orf34，DNAJB8，FTH1，GEMIN4，GIGYF2，GJC3，HTT，ITCH，MARK2，METT10D，NAV3，NOB1，PAFAH2，PLEKHG4B，PPFIA1，SCARNA11，SDF2L1，SMPD3，SNORA44，SRP14，ST6GALNAC1，SULF2， TMED6，TYRP1，WFDC13，ZNFX1，NCAM2，PCDH17，CHODL，BTG3，DIAPH3，GBA3，IFRD1，KCNT2，THOC7，TMEM168，BST1，C7orf53，CD38，DCUN1D1，FGFBP1，FOXP2，GLRB，GTF2B，HSP90AB2P，MCCC1，MDFIC， 从受试者收集的待检样本的ODF2L，PDGFC，SEP15，SH3GLB1，TDRD3，YEATS2，CCDC127，C14orf180，SIVA1，TNFRSF14，AHNAK2，C14orf79，LOC25845，PLD4，GPR132，LOC389257，BRF1和ADSSL1; 并将获得的结果与检测拷贝数变异与变应原免疫治疗的有效性相关联。